Abstract
BM failure (BMF) is a major and frequent complication of dyskeratosis congenita (DKC). Allogeneic hematopoietic SCT (allo-HSCT) represents the only curative treatment for BMF associated with this condition. Transplant-related morbidity/mortality is common especially after myeloablative conditioning regimens. Herein, we report nine cases of patients with DKC who received an allo-SCT at five different member centers within the Eastern Mediterranean Blood and Marrow Transplantation Registry. Between October 1992 and February 2011, nine DKC patients (male, 7 and female, 2), with a median age at transplantation of 19.1 (4.9–31.1) years, underwent an allo-HSCT from HLA-matched, morphologically normal-related donors (100%). Preparative regimens varied according to different centers, but was reduced intensity conditioning (RIC) in eight patients. Graft source was unstimulated BM in five cases (56%) and G-CSF-mobilized PBSCs in four (44%) cases. The median stem cell dose was 6.79 (2.06–12.4) × 106 cells/kg body weight. GVHD prophylaxis consisted of CsA in all nine cases; MTX or mycophenolate mofetil were added in five (56%) and two (22%) cases, respectively. Anti-thymocyte globulin was administered at various doses and scheduled in four (44%) cases. Median time-to-neutrophil engraftment was 21 (17–27) days. In one case, late graft failure was noted at 10.4 months post allo-HSCT. Only one patient developed grade II acute GVHD (11%). Extensive chronic GVHD was reported in one case, whereas limited chronic GVHD occurred in another four cases. At a median follow-up of 61 (0.8–212) months, seven (78%) patients were still alive and transfusion independent. One patient died of metastatic gastric adenocarcinoma and graft failure was the cause of death in another patient. This study suggests that RIC preparative regimens are successful in inducing hematopoietic cell engraftment in patients with BMF from DKC. Owing to the limited sample size, the use of registry data and heterogeneity of preparative as well as GVHD prophylaxis regimens reported in this series, we are unable to recommend a particular regimen to be considered as the standard for patients with this disease.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Zinsser F . Atrophia cutis reticularis cum pigmentations, dystrophia unguium et leukoplakis oris (Poikioodermia atrophicans vascularis Jacobi.). Ikonogr Dermatol 1910; 5: 219–223.
Savage SA . Dyskeratosis Congenita, In: Pagon RA, Bird TD, Dolan CR, Stephens K, (eds). Gene Reviews [Internet]. University of Washington: Seattle, WA, USA, 1993–2009.
Savage SA, Alter BP . Dyskeratosis congenita. Hematol Oncol Clin North Am 2009; 23: 215–231.
Kirwan M, Dokal I . Dyskeratosis congenita, stem cells and telomeres. Biochim Biophys Acta 2009; 1792: 371–379.
Auluck A . Dyskeratosis congenita. Report of a case with literature review. Med Oral Patol Oral Cir Bucal 2007; 12: E369–E373.
Knight SW, Vulliamy TJ, Morgan B, Devriendt K, Mason PJ, Dokal I . Identification of novel DKC1 mutations in patients with dyskeratosis congenita: implications for pathophysiology and diagnosis. Hum Genet 2001; 108: 299–303.
Nishio N, Kojima S . Recent progress in dyskeratosis congenita. Int J Hematol 2010; 92: 419–424.
De la Fuente J, Dokal I . Dyskeratosis congenita: advances in the understanding of the telomerase defect and the role of stem cell transplantation. Pediatr Transplant 2007; 11: 584–594.
Tolar J, Orchard PJ, Miller JS, MacMillan ML, Wagner JE, Alter BP et al. Dyskeratosis congenita: low regimen-related toxicity following hematopoietic cell transplantation (HCT) using a reduced intensity conditioning regimen. Blood 2007; 110: 2005.
Dror Y, Freedman MH, Leaker M, Verbeek J, Armstrong CA, Saunders FE et al. Low-intensity hematopoietic stem-cell transplantation across human leucocyte antigen barriers in dyskeratosis congenita. Bone Marrow Transplant 2003; 31: 847–850.
Berthou C, Devergie A, D’Agay MF, Sonsino E, Scrobohaci ML, Loirat C et al. Late vascular complications after bone marrow transplantation for dyskeratosis congenita. Br J Haematol 1991; 79: 335–336.
Dietz AC, Orchard PJ, Baker KS, Giller RH, Savage SA, Alter BP et al. Disease-specific hematopoietic cell transplantation: nonmyeloablative conditioning regimen for dyskeratosis congenita. Bone Marrow Transplant 2011; 46: 98–104.
Ghavamzadeh A, Alimoghadam K, Nasseri P, Jahani M, Khodabandeh A, Ghahremani G . Correction of bone marrow failure in dyskeratosis congenita by bone marrow transplantation. Bone Marrow Transplant 1999; 23: 299–301.
Kharfan-Dabaja MA, Otrock ZK, Bacigalupo A, Mahfouz RA, Geara F, Bazarbachi A . A reduced intensity conditioning regimen of fludarabine, cyclophosphamide, antithymocyte globulin, plus 2 Gy TBI facilitates successful hematopoietic cell engraftment in an adult with dyskeratosis congenita. Bone Marrow Transplant 2012; 47: 1254–1255.
Ayas M, Al-Musa A, Al-Jefri A, Al-Seraihi A, Al-Mahr M, Rifai S et al. Allogeneic stem cell transplantation in a patient with dyskeratosis congenita after conditioning with low-dose cyclophosphamide and anti-thymocyte globulin. Pediatr Blood Cancer 2007; 49: 103–104.
Fogarty PF, Yamaguchi H, Wiestner A, Baerlocher GM, Sloand E, Zeng WS et al. Late presentation of dyskeratosis congenita as apparently acquired aplastic anemia due to mutations in telomerase RNA. Lancet 2003; 362: 1628–1630.
Dokal I, Luzzatto L . Dyskeratosis congenita is a chromosomal instability disorder. Leuk Lymphoma 1994; 15: 1–7.
Rocha V, Devergie A, Socié G, Ribaud P, Espérou H, Parquet N et al. Unusual complications after bone marrow transplantation for dyskeratosis congenita. Br J Haematol 1998; 103: 243–248.
Savage SA, Dokal I, Armanios M, Aubert G, Cowen EW, Domingo DL et al. Dyskeratosis congenita: the first NIH clinical research workshop. Pediatr Blood Cancer 2009; 53: 520–523.
Brazzola P, Duval M, Fournet JC, Gauvin F, Dalle JH, Champagne MA et al. Fatal diffuse capillaritis after haematopoietic stem cell transplantation for dyskeratosis congenita despite low-intensity conditioningreg regimen. Bone Marrow Transplant 2005; 36: 1103–1105.
Amarasinghe K, Dalley C, Dokal I, Laurie A, Gupta V, Marsh J . Late death after unrelated-BMT for dyskeratosis congenita following conditioning with alemtuzumab, fludarabine and melphalan. Bone Marrow Transplant 2007; 40: 913–914.
Yabe M, Yabe H, Hattori K, Morimoto T, Hinohara T, Takakura I et al. Fatal interstitial pulmonary disease in a patient with dyskeratosis congenita after allogeneic bone marrow transplantation. Bone Marrow Transplant 1997; 19: 389–392.
Langston AA, Sanders JE, Deeg HJ, Crawford SW, Anasetti C, Sullivan KM et al. Allogeneic marrow transplantation for aplastic anaemia associated with dyskeratosis congenita. Br J Haematol 1996; 92: 758–765.
Bizzetto R, Bonfim C, Rocha V, Socié G, Locatelli F, Chan K et alEurocord and SAA-WP from EBMT. Outcomes after related and unrelated umbilical cord blood transplantation for hereditary bone marrow failure syndromes other than Fanconi anemia. Haematologica 2011; 96: 134–141.
Dokal I, Manning R, Laffan M . Elevated levels and multimer pattern of von Willebrand factor in patients with dyskeratosis congenita. Br J Haematol 1995; 89: 33.
Amrolia P, Gaspar HB, Hassan A, Webb D, Jones A, Sturt N et al. Nonmyeloablative stem cell transplantation for congenital immunodeficiencies. Blood 2000; 96: 1239–1246.
Gungor T, Corbacioglu S, Storb R, Seger RA . Nonmyeloablative allogeneic hematopoietic stem cell transplantation for treatment of dyskeratosis congenita. Bone Marrow Transplant 2003; 31: 407–410.
Paul SR, Perez-Atayde A, Williams DA . Interstitial pulmonary disease associated with dyskeratosis congenita. Am J Pediatr Hematol/Oncol 1992; 14: 89–92.
Utz JP, Ryu JH, Myers JL, Michels VV . Usual interstitial pneumonia complicating dyskeratosis congenita. Mayo Clin Proc 2005; 80: 817–821.
Alter BP, Giri N, Savage SA, Peters JA, Loud JT, Leathwood L et al. Malignancies and survival patterns in the National Cancer Institute inherited bone marrow failure syndromes cohort study. Br J Haematol 2010; 150: 179–188.
Artandi SE, DePinho RA . Telomeres and telomerase in cancer. Carcinogenesis 2010; 31: 9–18.
Shaw PH, Haut PR, Olszewski M, Kletzel M . Hematopoietic stem-cell transplantation using unrelated cord-blood versus matched sibling marrow in pediatric bone marrow failure syndrome: one center's experience. Pediatr Transplant 1999; 3: 315–321.
Velazquez I, Alter BP . Androgens and liver tumors: Fanconi's anemia and non-Fanconi's conditions. Am J Hematol 2004; 77: 257–267.
Giri N, Pitel PA, Green D, Alter BP . Splenic peliosis and rupture in patients with dyskeratosis congenita on androgens and granulocyte colony-stimulating factor. Br J Haematol 2007; 138: 815–817.
Vuong LG, Hemmati PG, Neuburger S, Terwey TH, Vulliamy T, Dokal I et al. Reduced-intensity conditioning using fludarabine and antithymocyte globulin alone allows stable engraftment in a patient with dyskeratosis congenita. Acta Haematol 2010; 124: 200–203.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Ayas, M., Nassar, A., Hamidieh, A. et al. Reduced intensity conditioning is effective for hematopoietic SCT in dyskeratosis congenita-related BM failure. Bone Marrow Transplant 48, 1168–1172 (2013). https://doi.org/10.1038/bmt.2013.35
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2013.35
Keywords
This article is cited by
-
Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022
Bone Marrow Transplantation (2022)
-
Antithymocyte globulin for graft-versus-host disease prophylaxis: an updated systematic review and meta-analysis
Bone Marrow Transplantation (2019)
-
Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019
Bone Marrow Transplantation (2019)
-
A unique homozygous WRAP53 Arg298Trp mutation underlies dyskeratosis congenita in a Chinese Han family
BMC Medical Genetics (2018)
-
Tacrolimus plus sirolimus with or without ATG as GVHD prophylaxis in HLA-mismatched unrelated donor allogeneic stem cell transplantation
Bone Marrow Transplantation (2017)